Reply to: Comment on: Comparison of hypersensitivity rates to intravenous and intramuscular PEG-asparaginase in children with acute lymphoblastic leukemia: A meta-analysis and systematic review-Reference-Cited by-同舟云学术

Reply to: Comment on: Comparison of hypersensitivity rates to intravenous and intramuscular PEG-asparaginase in children with acute lymphoblastic leukemia: A meta-analysis and systematic review

Published:2018-04-25 Issue:8 Volume:65 Page:e27106
ISSN:1545-5009
Container-title:Pediatric Blood & Cancer
language:en
Short-container-title:Pediatr Blood Cancer

Author:

Hasan Haroon¹²^ORCID,Shaikh Omar Mohammad³,Rassekh Shahrad Rod⁴⁵,Howard A. Fuchsia⁶^ORCID,Goddard Karen¹⁷

Affiliation:

1. Department of Radiation Oncology; British Columbia Cancer Agency Vancouver Centre; Vancouver British Columbia

2. Division of Clinical Epidemiology; Epi Methods Consulting; Toronto Ontario

3. Faculty of Health Sciences; McMaster University; Hamilton Ontario

4. Division of Oncology/Hematology/BMT; British Columbia Children's Hospital; Vancouver British Columbia

5. Department of Pediatrics; Faculty of Medicine; University of British Columbia; Vancouver British Columbia

6. School of Nursing; Faculty of Applied Sciences; University of British Columbia; Vancouver British Columbia

7. Department of Surgery; Faculty of Medicine; University of British Columbia; Vancouver British Columbia

Publisher

Wiley

Subject

Oncology,Hematology,Pediatrics, Perinatology and Child Health

Reference13 articles.

1. Comment on: Comparison of hypersensitivity rates to intravenous and intramuscular PEG-asparaginase in children with acute lymphoblastic leukemia: A meta-analysis and systematic review;Dholaria;Pediatr Blood Cancer,2018

2. Comparison of hypersensitivity rates to intravenous and intramuscular PEG-asparaginase in children with acute lymphoblastic leukemia: a meta-analysis and systematic review;Hasan;Pediatr Blood Cancer,2017

3. Intravenous pegylated asparaginase versus intramuscular native Escherichia coli L-asparaginase in newly diagnosed childhood acute lymphoblastic leukaemia (DFCI 05-001): a randomised, open-label phase 3 trial;Place;Lancet Oncol,2015

4. Incidence of allergic reactions to pegaspargase (PEG) administered intramuscularly versus intravenously (IM vs. IV) in children and young adults with high risk B-lymphoblastic leukemia (HR B-ALL): Results of children's oncology group (COG) studies AALL0232/AALL1131;Salzer;Blood,2015

5. Allergic reactions with intravenous compared with intramuscular pegaspargase in children with high-risk acute lymphoblastic leukemia: a population-based study from the Maritimes, Canada;MacDonald;J Pediatr Hematol Oncol,2016

Cited by 1 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Oncologist counseling practice and COVID‐19 vaccination outcomes for patients with history of PEG‐asparaginase hypersensitivity;Pediatric Blood & Cancer;2022-03-30